Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4412 25-years of experience with somatostatin receptor-based therapy in patients with small intestinal neuroendocrine tumours

Introduction: Small intestinal neuroendocrine tumours are well-differentiated and express type 2 somatostatin receptors (SSTR2). Treatment with somatostatin analogues (SSA) (octreotide or lanreotide) has been a cornerstone in controlling tumour growth for 25 years. Peptide Receptor Radionuclide Therapy (PRRT), utilising radiolabelled SSA, was introduced in our institution in May 2009 as primarily 2nd line treatment after progression on SSA. The standard PRRT regimen includes 4 cycles of PRRT (7.4 GBq 177Lu-DOTATATE every eight weeks). Re-treatment protocols remain debated.

Conference:

Presenting Author: Andreassen M

Authors: Slott C, Oturai P, Langer S, Møller S, Hansen C,

Keywords: SSA, PRRT, small intestinal NET,

#3780 Evaluation of tumor tissue miRNAs for assessing the grade of pancreatic neuroendocrine tumors from FFPE samples

Introduction: Our research aims were to determine whether the human tissue microRNAs miR-21, miR-96, miR-130b and miR-210 are of use in the differential diagnosis of grade 1 and grade 2 pancreatic neuroendocrine tumors (PNET).

Conference:

Presenting Author: Nyirő G

Authors: Nyirő G, Szeredás B, Moloney C, Turai P, Vékony B,

Keywords: PNET, FFPE, RT-QPCR, miR-21, miR-96, miR-130b, miR-210, miRNA, Grade 1, Grade 2,

#1419 Long Term Renal and Haematological Side Effects in NET patients Treated with Lu-177-DOTATATE

Introduction: Long term renal and bone marrow side effects may be a problem after PRRT.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Oturai P

Authors: Oturai P, De Nijs R, Klausen T, Holm S, Knigge U,

Keywords: prrt, dosimetry,